Etravirine

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Warnung

• Gefahrenhinweise

  H410：Sehr giftig für Wasserorganismen mit langfristiger Wirkung.

• Sicherheit

  P273：Freisetzung in die Umwelt vermeiden.

  P391：Verschüttete Mengen aufnehmen.

  P501：Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen.

Etravirine Chemische Eigenschaften,Einsatz,Produktion Methoden

• Beschreibung

  Etravirine is a second-generation NNRTI. It is indicated for use in combination with other antiretroviral agents for treating HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to the currently available NNRTIs and other antiretroviral agents. The NNRTIs, along with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs), are important components of the combination regimens currently used to treat HIV-1 infection. The NRTIs/NtRTIs act by competing with the natural nucleotide substrates of reverse transcriptase for incorporation into viral DNA and subsequent chain termination. By contrast, the NNRTIs bind to an allosteric site of the enzyme and disrupt the DNA polymerase function by inducing conformational changes to the catalytic site. The allosteric binding nature of NNRTIs generally results in improved safety profile since there is no known human homolog for the drug-binding site of the enzyme.
  As with other NNRTIs, etravirine has many drug–drug interactions. It is a substrate of CYP3A4, CYP2C9, and CYP2C19, an inducer of 3A4, and an inhibitor of 2C9 and 2C19. Caution should be used with co-administration of inducers, inhibitors, or substrates of these enzymes. Etravirine can be synthesized starting from 5-bromo-2,4,6-trichloropyrimidine through three successive nucleophilic substitution reactions. Initial displacement with 4-aminobenzonitrile using Hu¨nig’s base, followed by reaction with sodium salt of 4-hydroxy-3,5- dimethylbenzonitrile, and subsequent ammonolysis reaction with ammonia in dioxane under pressure affords etravirine. .

• Chemische Eigenschaften

  White to Off-White Solid

• Originator

  Janssen (United States)

• Verwenden

  Etravirine is a novel HIV reverse transcriptase inhibitor useful in treatment of HIV infection.

• Verwenden

  Etravirine (TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV.

• Verwenden

  Etravirine is an antiretroviral (anti-HIV) drug that is part of the non nucleoside reverse transcriptase inhibitor (NNRTIs or Non Nukes) family. It is used together with other antiretrovirals in treatment-experienced adult patients, who have failed previous therapy, and have HIV-1 strains which are resistant to other retrovirals and NNRTIs. Etravirine is used to delay the progression of HIV infection. By using etravirine, your immune system should improve (increase in CD4 + count) and you will be better protected against opportunistic infections.
  Etravirine does not cure AIDS or completely kill the HIV virus, but helps to prevent further damage by slowing down the production of new viruses. Treatment with etravirine does not reduce the risk of passing infection on to others. You will still be able to pass HIV by sexual contact, by blood transfer or by sharing needles. You should always use appropriate precautions to prevent passing HIV on to others.

• Definition

  ChEBI: An aminopyrimidine that consists of 2,6-diaminopyrimidine bearing a bromo substituent at position 5, a 4-cyano-2,6-dimethylphenoxy substituent at position 4 and having a 4-cyanophenyl substituent attached to the 2-amino group. NNRTI of HIV-1, binds directl to RT and blocks RNA-dependent and DNA-dependent DNA polymerase activities

• Trademarks

  Intelence

• Acquired resistance

  Various mutations are associated with a decreased virological response. Single codon substitutions at positions 100, 101 and 181 are considered major mutations. A single K103N mutation is not associated with resistance.

• Pharmazeutische Anwendungen

  A comprehensive analysis of baseline resistance data from the DUET-1 and DUET-2 studies has identified a list of 17 etravirine resistance associated mutations: V901, A98G, L100L, K101E/H/I, V1061, E138A, V179D/F/T, Y181C/L/V, G190A/S, and M230L. A single K103N mutation is not associated with resistance to etravirine.

• Mechanism of action

  Etravirine binds directly to reverse transcriptase and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. Etravirine does not inhibit the human DNA polymerases alpha, beta, and gamma.

• Pharmakokinetik

  Oral absorption: Not known/available
  C_max 200 mg oral twice daily: c. 959 ng/mL
  C_min 200 mg oral twice daily: c. 469 ng/mL
  Plasma half-life: c. 36 h
  Volume of distribution: Not known/available
  Plasma protein binding: >99%
  Administration with food improves the bioavailability and reduces interpatient variability. It undergoes oxidative metabolism by cytochrome P₄₅₀ systems. Around 93.7% and 1.2% of an administered dose can be retrieved in the feces and urine, respectively, mostly as unchanged drug.
  Details of distribution into CSF, semen and breast milk and recommendations for dose adjustment in patients with hepatic impairment are not yet available.

• Clinical Use

  Treatment of HIV-1 infection in adults (in combination with other antiretroviral drugs)

• Nebenwirkungen

  In the phase III studies around 15% of patients experienced erythematous or maculopapular rashes of mild or moderate severity; most resolved with continued dosing, but treatment was discontinued in 2% of patients. Rare cases of Stevens– Johnson syndrome have been reported.
  Other common adverse events are diarrhea, nausea, headache and fatigue. Dyslipidemia and raised pancreatic amylase occur in some patients.

• Synthese

  Only the discovery synthesis and small scale syntheses have been disclosed for this compound in the following scheme. The largest scale synthesis was initiated by the portionwise addition of cyanamide to a solution of the p-cyanoaniline hydrochloride salt 73. The mixture was refluxed in diglyme to give guanidine salt 74 in 85% yield after concentration of the reaction mixture and recrystallization from acetone. Reaction of guanidine 74 with diethylmalonate in the presence of sodium ethoxide in refluxing ethanol gave pyrimidine diol 75 in 57% yield, which upon refluxing in phosphorous oxychloride for 30 min gave dichloride 76 in 97% yield. Bromination of dichloride 76 with NBS in chloroform at room temperature provided bromide 77 in 55% yield. Heating a mixture of the dichlorobromide 77 with the sodium salt of 2,5-dimethyl-4-cyanophenol 78, generated by reaction with sodium hydride in situ) in diglyme and NMP at 155 ??C gave the coupled product 79 in 45% yield. Finally, reaction of the chloride 79 with ammonia in refluxing dioxane (or iPrOH) in a sealed tube gave etravirine (IX) in 41% yield after purification.

  

• Arzneimittelwechselwirkung

  Potentially hazardous interactions with other drugs
  Antibacterials: concentration increased by clarithromycin, also concentration of clarithromycin reduced; concentration of both drugs reduced with rifabutin; avoid concomitant use with rifampicin
  . Antivirals: concentration possibly reduced by efavirenz and nevirapine - avoid concomitant use; concentration of fosamprenavir increased, consider reducing fosamprenavir dose; possibly reduces bosutinib and indinavir concentration - avoid concomitant use; concentration of dolutegravir reduced; possibly reduces concentration of maraviroc; concentration reduced by tipranavir and tipranavir concentration increased - avoid concomitant use.
  Clopidogrel: possibly reduced antiplatelet effect.
  Guanfacine: possibly reduces concentration of guanfacine - increase guanfacine dose.
  Orlistat: absorption possibly reduced by orlistat.

• Stoffwechsel

  Etravirine is extensively metabolised by hepatic microsomal enzymes, mainly by the cytochrome P450 isoenzymes CYP3A4, CYP2C9, and CYP2C19, to substantially less active metabolites.
  Unchanged etravirine accounted for 81.2-86.4% of the administered dose in faeces. Unchanged etravirine was not detected in urine.

Etravirine Upstream-Materialien And Downstream Produkte

Etravirine Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(260)Suppliers

269055-15-4, Etravirine Verwandte Suche: